Lanzhou Foci Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2020
October 20, 2020 at 02:19 pm IST
Share
LanZhou Foci Pharmaceutical Co.,Ltd. announced earnings results for the nine months ended September 30, 2020. For the nine months, the company announced sales was CNY 502.304 million compared to CNY 467.533 million a year ago. Operating income was CNY 127.559 million compared to CNY 85.589 million a year ago. Net income was CNY 108.144 million compared to CNY 72.986 million a year ago. Basic earnings per share from continuing operations was CNY 0.2118 compared to CNY 0.1429 a year ago.
LanZhou Foci Pharmaceutical Co.,Ltd is a China-based company principally engaged in the research, development, manufacture and sale of Chinese patent drugs and large health products. The Companyâs main products are categorized into pills, tablets, granules, syrups, capsules, glue and others, including Liuwei Dihuang pills, Xiaoyao Pill, Xiangsha Yangwei pills, ginseng Gubeng Huanhao pills and other Chinese patent drugs, as well as large health products, such as Ejiao and Ejiao loafs. The Company distributes its products under the brand names Foci, Baolu and Mianshan. The Company is also involved in the cultivation, processing and marketing of Chinese herbal medicine. The Company distributes its products in domestic market and to overseas markets.
LANZHOU FOCI PHARMACEUTICAL CO.,LTD. 
